An evaluation of taletrectinib for the treatment of ROS1+ non-small cell lung cancer.

introductionROS1 fusion - positive non-small cell lung cancer (NSCLC) represents a rare but clinically important subset, occurring in 1-2% of patients and often associated with younger, never-smoker populations. Current first-generation tyrosine kinase inhibitors (TKIs) such as crizotinib and entrectinib provide meaningful benefit but are limited by poor central nervous system (CNS) penetration and the development of resistance mutations, particularly G2032R. AREAS COVERED: This review evaluates the development, pharmacologic properties, and clinical outcomes of taletrectinib, a next-generation ROS1 inhibitor recently approved by the FDA. Taletrectinib demonstrated high objective response rates in both TKI-naïve (88.8%) and TKI-pretreated (55.8%) patients, including robust intracranial activity and efficacy against the G2032R mutation. The safety profile is favorable, with predominantly low-grade gastrointestinal and hepatic adverse events and minimal neurologic toxicity. EXPERT OPINION: Taletrectinib addresses major limitations of earlier ROS1 inhibitors by combining systemic potency, CNS activity, and tolerability. While its approval represents a significant advance for ROS1+ NSCLC, challenges remain, including resistance mechanisms such as L2086F, limited global access, and the absence of phase III confirmatory trials. Ongoing research into sequencing strategies, resistance profiling, and novel combination regimens will be essential to optimize patient outcomes.